摘要
目的:系统评价国内人群应用孟鲁司特钠治疗慢性阻塞性肺疾病有效性及安全性。方法:计算机检索中国生物医学、文献数据库(CBM)、中国知网全文数据库(CNKI)、维普中文期刊数据库(VIP)、万方数据库等数据库,收集孟鲁司特钠治疗慢性阻塞性肺疾病的随机对照试验。系统筛选文献、提取资料及评价质量后,对同质研究采用RevMan 5.0软件进行Meta分析.结果:共纳入6项研究,4]8例患者。Meta分析结果显示,盂鲁司特钠在提高FEV1/FVC方面优于对照组,两组间比较差异有统计学意义[MD=3.39,95%CI(2.00,4.79),P<0.00001];孟鲁司特钠能更好的改善FEV1%[MD=7.06,95%CI(5.21,8.91),P<0.00001]及提高PaO_2[MD=4.32,95%CI(2.77,5.86),P<0.00001]。结论:孟鲁司特钠治疗慢性阻塞性肺疾病疗效较为确切,但纳入研究较少、研究质量较低,结果还有待高质量、大样本的随机双盲对照试验加以验证。
Objective: To systematically evaluate the efficacy and safety of montelukast for chronic obstructive pulmonary disease in China. Method: Randomized controlled trials (RCTs)retrieved from CBM, CNKI, VIP and Wanfang on montelukast for chronic ob- structive pulmonary disease were included. Meta-analysis was carried out for homogeneity study using RevMan 5.0 software after sys- tematical study selection, data extraction and quality evaluation. Result: Totally 6 RCTs were included involving 418 patients. Meta-a- nalysis indicated the differences in FEV1/FVC [ MD = 3.39,95% CI (2. 00,4. 79), P 〈 0. 000 01 ], FEV1% [ MD = 7.06,95% CI ( 5.21,8.91 ), P 〈 0. 000 01 ] and PaO2 [ MD = 4. 32,95 % CI ( 2. 77,5.86 ), P 〈 0. 000 01 ] were significant. Conclusion : Monte- lukast is effective in the treatment of chronic obstructive pulmonary disease. Due to few included studies and generally poor quality of the studies, the above results need to be verified by high quality and large sample randomized double blind controlled studies.
出处
《中国药师》
CAS
2013年第10期1562-1565,共4页
China Pharmacist
关键词
孟鲁司特钠
慢性阻塞性肺疾病
系统评价
Montelukast
Chronic obstructive pulmonary disease
Systematic review